Hydroxychloroquine

Generic Name: Hydroxychloroquine

Brand Names: Plaquenil, Sovuna

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₆ClN_₃O

CAS Number: 118-42-3

Unique Ingredient Identifier: 4QWG6N8QKH

Background: Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.

The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.

Hydroxychloroquine was granted FDA approval on 18 April 1955.

A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.

Indication: Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

Associated Conditions: Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum

Clinical Trials

Autophagy Maintenance (AUTOMAIN)

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Hydroxychloroquine
Drug: Nelfinavir
Drug: Bevacizumab

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 20

Registration Number: NCT06971744

Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis

Phase 1

Recruiting

Conditions: Radiation-induced Oral Mucositis

Interventions: Other: Placebo
Drug: Hydroxychloroquine Sulfate Tablets

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-29

Lead Sponsor: Xingchen Peng

Target Recruit Count: 158

Registration Number: NCT06939582

Locations: 🇨🇳
Department of Radiation Oncology, Chengdu, Sichuan, China

Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

Phase 2

Not yet recruiting

Conditions: Primary Sjögren's Syndrome (pSS)

Interventions: Drug: Upadacitinib (ABT-494)
Drug: Hydroxychloroquine (HCQ)

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-11

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 30

Registration Number: NCT06862284

Locations: 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China

A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease

Phase 2

Not yet recruiting

Conditions: Parkinson&Amp;#39;s Disease

Interventions: Drug: Hydroxychloroquine (HCQ)

First Posted Date: 2025-02-10

Last Posted Date: 2025-02-10

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 40

Registration Number: NCT06816810

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

Baricitinib in CPPD - the BAPTIST Study

Phase 2

Not yet recruiting

Conditions: Calcium Pyrophosphate Deposition Disease
Chondrocalcinosis

Interventions: Drug: Baricitinib 4 MG Oral Tablet
Drug: Methylprednisolone (Corticosteroid)
Drug: Colchicine 1 MG Oral Tablet
Drug: Hydroxychloroquine 200 mg
Combination Product: Methotrexate + Folic Acid

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Target Recruit Count: 32

Registration Number: NCT06768294

Locations: 🇮🇹
IRCCS Galeazzi - Sant Ambrogio Hospital, Milan, Italy

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate At Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Phase 4

Not yet recruiting

Conditions: IgA Nephropathy
Renal Insufficiency, Chronic
IgA Vasculitis
IGA Glomerulonephritis

Interventions: Drug: Non-steroidal mineralocorticoid receptor antagonist and SoC
Drug: SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)
Drug: Oral prednisolone and SoC
Drug: Gut-directed budesonide and SoC
Drug: Mycophenolate mofetil (MMF) and SoC
Drug: Hydroxychloroquine and SoC

First Posted Date: 2024-11-06

Last Posted Date: 2024-11-06

Lead Sponsor: Christian Medical College, Vellore, India

Target Recruit Count: 585

Registration Number: NCT06676384

Locations: 🇮🇳
Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India
🇮🇳
JSS Medical College, Mysuru, Karnataka, India
🇮🇳
Kasturba Medical College, Manipal, Udupi, Karnataka, India

and more 9 locations

Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab

Not Applicable

Not yet recruiting

Conditions: Recurrent Pregnancy Loss
Euthyroid With Thyroid Antibodies

Interventions: Drug: hydroxychloroquine and levothyroxine
Drug: Levothyroxine

First Posted Date: 2024-10-22

Last Posted Date: 2024-10-22

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 796

Registration Number: NCT06652113

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage

Phase 2

Conditions: Primary Sjögren Syndrome

Interventions: Drug: Yi Qi Yang Yin Decoction
Drug: Hydroxychloroquine Sulfate

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: Qingwen Tao

Target Recruit Count: 136

Registration Number: NCT06519617

Locations: 🇨🇳
China-Japan friendship hospital, Beijing, Beijing, China

a Retrospective Study on the Systemic Treatment of LPP and FFA

Completed

Conditions: Cicatricial Alopecia
Lichen Planopilaris
Lichen Plano-Pilaris
Frontal Fibrosing Alopecia
Hair Diseases
Scarring Alopecia
Hair Loss/Baldness